Life Sciences Tools and Services
Company Overview of Crown Bioscience, Inc.
Crown Bioscience, Inc., a preclinical CRO, provides drug discovery and development services to biotech and pharmaceutical partners focusing on oncology and metabolic disease therapeutic areas. The company’s proprietary HuPrime, HuKemia, HuBase, HuMark, HuTrial, and HuSignature platforms enable lead optimization and translational strategies to deliver clinical candidates. It offers oncology services, such as oncology databases, Ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical formulations, translational research, and drug discovery services; and metabolic disease services, including in vivo and in vitro services, cardiovascular and metabolic disease (CVMD) ...
3375 Scott Boulevard
Santa Clara, CA 95054
Founded in 2006
Key Executives for Crown Bioscience, Inc.
Co-Founder, President and Chief Strategy Officer
President of International Institute of Biomedical Research (IIBR) and Senior Vice President of Cardiovascular & Metabolic Diseases (CVMD) Research
Compensation as of Fiscal Year 2016.
Crown Bioscience, Inc. Key Developments
CrownBio Presents at Annual China Healthcare Investment Conference, Mar-29-2017 09:30 AM
Mar 25 17
CrownBio Presents at Annual China Healthcare Investment Conference, Mar-29-2017 09:30 AM. Venue: Shangri-La Pudong Hotel, Shanghai, China. Speakers: Qian Shi, VP, Oncology.
Crown Bioscience Announces the Promotion of Dr. Jayant Thatte to General Manager
Mar 16 17
Crown Bioscience a wholly-owned subsidiary of Crown Bioscience International announced the promotion of Dr. Jayant Thatte to General Manager, heading up the company's center of excellence in San Diego. Dr. Thatte is an immunologist with 20 years of research experience in both academia and industry, focusing on cancer, autoimmunity, inflammation and pain. As Director of R&D and Associate Director of Operations at Molecular Response, he led the pharmacology team for numerous client projects that significantly increased revenue growth for the company, which ultimately resulted in the acquisition of PDX business by Crown Bioscience.
Crown Bioscience Announces Expansion of Therapeutic Expertise into Inflammation; Appoints Joel Tocker as Executive Director, Head of Inflammation
Jan 24 17
Crown Bioscience announced the expansion of its services into a novel therapeutic area, launching an Inflammatory Disease Division.
Following significant growth in 2016, and with increasing demand for its Translational, Immuno-Oncology, and Cardiovascular and Metabolic Disease services and models, CrownBio is expanding its offering to include Inflammation lead by the appointment of Dr. Joel Tocker as Executive Director, Head of Inflammation. Tocker brings significant experience in the field of Inflammation, having previously directed the preclinical
development of molecules targeting autoimmune, inflammatory, and respiratory disease at Janssen and lead projects targeting immune regulatory molecules in inflammatory and pulmonary disease at Amgen.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|